Abstracts tagged "registry and rheumatoid arthritis (RA)"

Abstract Number: 455 • 2015 ACR/ARHP Annual Meeting
Predictors of Real-World Treatment Sustainability in RA Patients Treated with Abatacept in Canada: Implications for Routine Care
Janet E. Pope¹, Emmanouil Rampakakis² and John S. Sampalis³, ¹University of Western Ontario, London, ON, Canada, ²JSS Medical Research, St-Laurent, QC, Canada, ³Clinical Research, JSS Medical Research, Westmount, QC, Canada
Background/Purpose: Treatment sustainability can measure drug effectiveness and encompasses drug effectiveness, safety, and compliance. Recent data suggest that differences in retention may exist between biologic…
Abstract Number: 459 • 2015 ACR/ARHP Annual Meeting
The Effect of Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Positivity on Drug Survival of Abatacept in Patients with Rheumatoid Arthritis in Routine Care: The Results from Turkbio Registry
Ihsan Ertenli¹, Omer Karadag¹, Yavuz Pehlivan², Ediz Dalkilic³, Ahmet Mesut Onat⁴, Bunyamin Kisacik⁵, Gercek Can⁶, Servet Akar⁷, Sedat Capar⁸, Umut Kalyoncu¹, Mustafa Ferhat Oksuz⁹, Emine Figen Tarhan⁷ and Nurullah Akkoc⁶, ¹Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ²Department of Rheumatology, Uludag University Faculty of Medicine, Bursa, Turkey, ³Department of Rhematology, Uludag University Faculty of Medicine, Bursa, Turkey, ⁴Rheumatology, Gaziantep University School of Medicine, Gaziantep, Turkey, ⁵Rheumatology Department, Gaziantep University School of Medicine, Gaziantep, Turkey, ⁶Department of Rheumatology, Dokuz Eylul University, Faculty of Medicine, Izmir, Turkey, ⁷Department of Internal Medicine, Division of Rheumatology, Izmir Katip Celebi University School of Medicine, Izmir, Turkey, ⁸Dokuz Eylül University Faculty of Statistics, Izmir, Turkey, ⁹Rheumatology, Uludag University Faculty of Medicine, Bursa, Turkey
Background/Purpose: Abatacept (ABA) is a biological anti-rheumatic drug used in Rheumatoid Arthritis (RA). In TURKBIO, Turkish Biologic Registry, data on patient characteristics, diagnosis, previous treatment…
Abstract Number: 478 • 2015 ACR/ARHP Annual Meeting
Impact of Comorbidities on the Multi-Biomarker Disease Activity Test in Rheumatoid Arthritis Patients
Jeffrey R. Curtis¹, Jeffrey D. Greenberg², Leslie Harrold³ and J. Lynn Palmer⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²Corrona, LLC, Southborough, MA, ³Department of Medicine, UMass Memorial Medical Center, Worcester, MA, ⁴Corrona Research Foundation, Albany, NY
Background/Purpose: The multi-biomarker disease activity (MBDA) score [Vectra] has been evaluated in a number of settings, yet has only limited data evaluating whether it is…
Abstract Number: 488 • 2015 ACR/ARHP Annual Meeting
Six-Year Retention Rates with Abatacept Vs TNF Inhibitors in the Treatment of Rheumatoid Arthritis: Experience from the Real-World Rhumadata Clinical Database and Registry
Denis Choquette¹, Louis Bessette², Boulos Haraoui³, Jean-Pierre Raynauld¹, Diane Sauvageau¹, Angèle Turcotte⁴, Édith Villeneuve¹ and Louis Coupal¹, ¹Rheumatology, Institut de recherche en rhumatologie de Montréal (IRRM), Montréal, QC, Canada, ²Centre d’Ostéoporose et de Rhumatologie de Québec (CORQ), Québec, QC, Canada, ³Université de Montréal, Montreal, QC, Canada, ⁴Rheumatology, Centre d’ostéoporose et de rhumatologie de Québec (CORQ), Québec, QC, Canada
Background/Purpose: The sustainability of any regimen is an important factor to consider when selecting therapy for chronic conditions, such as rheumatoid arthritis (RA). Recent reports…
Abstract Number: 497 • 2015 ACR/ARHP Annual Meeting
Treatment Outcomes in Elderly Patients with Rheumatoid Arthritis: Results from a Nationwide Korean Biologics Registry
Seung Min Jung¹, Ji Yeon Lee¹, Jung Hee Koh¹, Seung-Ki Kwok², Ji Hyeon Ju¹, Chong-Hyeon Yoon¹ and Sung-Hwan Park¹, ¹Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ²[email protected], Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease, predominantly affecting women in their fifth and sixth decades of life. Although population aging increases the…
Abstract Number: 599 • 2015 ACR/ARHP Annual Meeting
An Examination of Dose Escalation Among Remicade (infliximab) Users in a US RA Registry
Jeffrey R. Curtis¹, Ying Shan², Joel M. Kremer³, Katherine Saunders⁴, Dennis Parenti⁵ and Shelly Kafka⁵, ¹University of Alabama at Birmingham, Birmingham, AL, ²UMass Memorial Medical Center, Worcester, MA, ³Albany Medical College, Albany, NY, ⁴Corrona LLC, Atlanta, GA, ⁵Janssen Scientific Affairs, LLC, Horsham, PA
Background/Purpose: Limited data are available about infliximab(IFX) dose escalation. This analysis examines the frequency of dose escalation among IFX patients using data from the US…
Abstract Number: 1437 • 2015 ACR/ARHP Annual Meeting
Prevalence of Pain, Its Impact and Management in a Population-Based Cohort of Patients with Rheumatoid Arthritis: Data from the Australian Rheumatology Association Database
Bethan Richards^1,2, Rachelle Buchbinder³, Marissa N. Lassere⁴ and Lyn March⁵, ¹Sydney Medical School, University of Sydney, Sydney, Australia, ²Royal Prince Alfred Hospital, Mulgrave, Vic, Australia, ³Monash Department of Clinical Epidemiology, Cabrini Institute and Monash University, Melbourne, Australia, ⁴Dept of Rheumatology, St George Hospital, Kogarah, Australia, ⁵Department of Rheumatology, Northern Clinical School, Institute of Bone and Joint Research, Kolling Institute, University of Sydney & Department of Rheumatology, Royal North Shore Hospital, St Leonards, Sydney, Australia
Background/Purpose: Despite advances in the treatments available for rheumatoid arthritis (RA), many patients continue to experience musculoskeletal pain. Untreated and under-treated pain are well known to increase…
Abstract Number: 1597 • 2015 ACR/ARHP Annual Meeting
Variability in Health Assessment Questionnaire Based on Type of Health Insurance Coverage and Rheumatology Practice
Jacqueline Stewart¹, Regan Arendse², Boulos Haraoui³, Michael Starr⁴, Denis Choquette⁵, Michelle Teo⁶, Dalton Sholter⁷, Emmanouil Rampakakis⁸, Eliofotisti Psaradellis⁹, Brendan Osborne¹⁰, Karina Maslova¹¹, Cathy Tkaczyk¹⁰, Francois Nantel¹² and Allen J Lehman¹¹, ¹Penticton Regional Hospital, Penticton, BC, Canada, ²University of Saskatchewan, Saskatoon, SK, Canada, ³Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, ⁴Rheumatology, McGill University, Montreal, QC, Canada, ⁵Rheumatology Department, Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, ⁶Rheumatology, Penticton Regional Hospital, Penticton, BC, Canada, ⁷Rheumatology Associates, Edmonton, AB, Canada, ⁸JSS Medical Research, St-Laurent, QC, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹¹Janssen Inc., Toronto, ON, Canada, ¹²19 Green belt Dr, Janssen Inc., Toronto, ON, Canada
Background/Purpose : Previous studies in rheumatoid arthritis (RA) have shown that patient socioeconomic status (SES) impacts patient prognosis. We hypothesized that public vs. private healthcare…
Abstract Number: 2669 • 2015 ACR/ARHP Annual Meeting
Persistency of Patient Reported Morning (AM) Stiffness in a Large US Registry Cohort of Rheumatoid Arthritis (RA) Patients Initiating New DMARD Therapy
Vibeke Strand¹, Robert J. Holt², Heather J. Litman³, Jeffrey D. Kent⁴, Hristina Pashova⁵, John T. Nguyen³ and Carol J. Etzel^6,7, ¹Division of Immunology/Rheumatology, Stanford University School of Medicine, Portola Valley, CA, ²University of Illinois - Chicago, Chicago, IL, ³Corrona, LLC., Southborough, MA, ⁴Horizon Pharma USA, Inc., Deerfield, IL, ⁵Axio Research, LLC., Seattle, WA, ⁶The University of Texas MD Anderson Cancer Center, Houston, TX, ⁷Corrona, LLC, Southborough, MA
Background/Purpose: AM stiffness is a common yet under-appreciated symptom in RA. The longitudinal impact of AM stiffness has not been previously investigated. This study evaluated…
Abstract Number: 1537 • 2014 ACR/ARHP Annual Meeting
Clinical Characteristics of RA Patients Newly Prescribed Tofacitinib Citrate (tofacitinib) in the United States after Food and Drug Administration Approval: Results from the Corrona US Rheumatoid Arthritis Registry
Arthur Kavanaugh¹, George W. Reed^2,3, Katherine C. Saunders², Andrew S. Koenig⁴, Jamie Geier⁵, Joel M. Kremer⁶, Jeffrey D. Greenberg^2,7 and Clifton O. Bingham III⁸, ¹University of California San Diego, La Jolla, CA, ²Corrona, LLC., Southborough, MA, ³University of Massachusetts Medical School, Worcester, MA, ⁴Pfizer, Inc., Collegeville, PA, ⁵Pfizer, Inc., New York, NY, ⁶Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY, ⁷Rheumatology, New York University School of Medicine, New York, NY, ⁸Johns Hopkins University, Baltimore, MD
Background/Purpose: To provide initial characterization of the patients prescribed tofacitinib during the early period after United States (US) Food and Drug Administration (FDA) approval (11/6/2012).…
Abstract Number: 1397 • 2014 ACR/ARHP Annual Meeting
Impact of Corticosteroid Use on Remission Sustainability and Infection Rates Among Rheumatoid Arthritis Patients in Remission While on Infliximab: Treatment Implications Based on a Real-World Canadian Population
Boulos Haraoui¹, Algis Jovaisas², William G. Bensen³, Rafat Faraawi⁴, John Kelsall⁵, Sanjay Dixit⁴, Jude Rodrigues⁶, Maqbool Sheriff⁷, Emmanouil Rampakakis⁸, John S. Sampalis⁸, Allen J Lehman⁹, Susan Otawa⁹, Francois Nantel¹⁰ and May Shawi¹⁰, ¹Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, ²Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada, ³Department of Medicine, Division of Rheumatology, St. Joseph's Hospital and McMaster University, Hamilton, ON, Canada, ⁴McMaster University, Hamilton, ON, Canada, ⁵The Mary Pack Arthritis Centre, Vancouver, BC, Canada, ⁶Clinical Research and Arthritis Centre, Windsor, ON, Canada, ⁷Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁸JSS Medical Research, Montreal, QC, Canada, ⁹Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada
Background/Purpose The Canadian Rheumatology Association1 recommends that addition of corticosteroids (CS) should be considered only for the shortest period possible in rheumatoid arthritis (RA) patients…
Abstract Number: 1069 • 2014 ACR/ARHP Annual Meeting
Impact of Rheumatoid Arthritis on the Mortality of Patients Who Develop Cancer: A Population-Based Study
Pratibha Nayak¹, Ruili Luo², Linda Elting² and Maria E. Suarez-Almazor³, ¹General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ²The Department of Health Services Research, The University of Texas, MD Anderson Cancer Center, Houston, TX, ³The Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX
Background/Purpose Comorbidity among cancer patients imposes additional risks for premature mortality. The specific effect of rheumatoid arthritis (RA) on survival among cancer patients is unknown.…
Abstract Number: 501 • 2014 ACR/ARHP Annual Meeting
Bio-naïve Patients with Rheumatoid Arthritis Benefit More from Abatacept Treatment Compared to Those Who Are Inadequate Responders to Other Biologics – Results from the National Swedish Rheumatology Quality Register
Carl Turesson¹, Leszek Stawiarz², Staffan Lindblad³ and Saedis Saevarsdottir⁴, ¹Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ²Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden, ³Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden, ⁴Rheumatology Unit, Department of Medicine, Karolinska institutet and Karolinska University Hospital, Stockholm, Sweden
Background/Purpose Abatacept is a biological anti-rheumatic drug used in Rheumatoid Arthritis (RA). Data on patient characteristics, diagnosis, previous treatment and outcomes of abatacept have been…
Abstract Number: 510 • 2014 ACR/ARHP Annual Meeting
Similar Short Term Survival on Drug for Patients with Rheumatoid Arthritis Treated with Subcutaneous and Intravenous Abatacept – Results from the National Swedish Rheumatology Quality Register
Carl Turesson¹, Leszek Stawiarz², Staffan Lindblad³ and Saedis Saevarsdottir⁴, ¹Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ²Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden, ³Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden, ⁴Rheumatology Unit, Department of Medicine, Karolinska institutet and Karolinska University Hospital, Stockholm, Sweden
Background/Purpose Abatacept is a biological anti-rheumatic drug used in Rheumatoid Arthritis (RA). Data on patient characteristics, diagnosis, previous treatment and outcomes of abatacept have been…
Abstract Number: 418 • 2014 ACR/ARHP Annual Meeting
Prevalence of Morning Stiffness in a US Registry Population of Rheumatoid Arthritis Patients
Vibeke Strand¹, Robert J. Holt², Katherine C. Saunders³, Jeffery D. Kent⁴, Ping Xu⁵, Amy Y. Grahn⁴, Marc Mason³ and Carol J. Etzel^6,7, ¹Stanford University, Palo Alto, CA, ²University of Illinois - Chicago, Chicago, IL, ³Corrona, LLC., Southborough, MA, ⁴Horizon Pharma, Inc., Deerfield, IL, ⁵Axio Research LLC, Seattle, WA, ⁶PO Box 786, Corrona, LLC., Southborough, MA, ⁷Department of Epidemiology, UT MD Anderson, Houston, TX
Background/Purpose : Morning stiffness is a symptom of rheumatoid arthritis (RA) that is frequently reported and thought to reflect disease activity, but its etiology is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].